The LP002 "Bridge Test" data is due out by the end
Post# of 30028
Posted On: 09/26/2014 9:57:20 AM
The LP002 "Bridge Test" data is due out by the end of Q3, which is next Tuesday. Gerald has said this at least 2 or 3 times. He mentioned they had completed enrollment a couple weeks ago, and since this is just a blood test, it is very possible the data will be ready in the next few days.
The data will be univariant instead of multivariant. Therefore, we won't be getting numbers in the mid 90s, they'll be in the 70s and 80s, which for univariant are excellent! Hopefully shareholders will be more aware of this than they were in July.
But Gerald has stated in the past that following the release of this data, there will be some "concrete" things that they can do regarding their LymPro partner that will increase shareholder value. Frankly, I have no idea what Gerald is talking about. His communication on this matter is encoded, "Geraldspeak" if you will. He has said contradictory things such as: our relationship with ICON could turn into a JV partnership, but he's also said that we'll start getting bids on LYmPro from BP that want to use it exclusively for themselves, suggesting a possible sale of LymPro down the road. So Gerald has been all over the board on this. But, he has consistently said that something will happen following the release of this data. I've seen him say this in a recent email as well!
We'll be getting another ocular MANF indication on October 6th. I can't really gauge how much this will give us a pop.
Gerald has stated that all of our milestones are on target and that they still plan on up listing in Q4. (Although January 2015 has been mentioned recently). He stated a month ago that we may not even need a RS to up list!! I think this was more of a rhetoric statement that has been taken literally, but nevertheless, Gerald has stated that he has catalysts that he believes will substantially increase shareholder value before year end.
So far the pps hasn't really gone anywhere in 2014, the Break Out Year for AMBS. We started in January in the .10 to 13 cent range, and we are still hovering at .10 cents now. For the market to give credence to Gerald's future guidance, it really needs to see some increase in shareholder value pretty soon! Maybe the $2.00 pps hope by December was childish gullibility on the parts of some shareholders. But Gerald himself is responsible for building shareholder expectations that our pps would be much higher than .10 cents by Q4 2014 when we're expected to up list.
Let's get the show on the road!!
The data will be univariant instead of multivariant. Therefore, we won't be getting numbers in the mid 90s, they'll be in the 70s and 80s, which for univariant are excellent! Hopefully shareholders will be more aware of this than they were in July.
But Gerald has stated in the past that following the release of this data, there will be some "concrete" things that they can do regarding their LymPro partner that will increase shareholder value. Frankly, I have no idea what Gerald is talking about. His communication on this matter is encoded, "Geraldspeak" if you will. He has said contradictory things such as: our relationship with ICON could turn into a JV partnership, but he's also said that we'll start getting bids on LYmPro from BP that want to use it exclusively for themselves, suggesting a possible sale of LymPro down the road. So Gerald has been all over the board on this. But, he has consistently said that something will happen following the release of this data. I've seen him say this in a recent email as well!
We'll be getting another ocular MANF indication on October 6th. I can't really gauge how much this will give us a pop.
Gerald has stated that all of our milestones are on target and that they still plan on up listing in Q4. (Although January 2015 has been mentioned recently). He stated a month ago that we may not even need a RS to up list!! I think this was more of a rhetoric statement that has been taken literally, but nevertheless, Gerald has stated that he has catalysts that he believes will substantially increase shareholder value before year end.
So far the pps hasn't really gone anywhere in 2014, the Break Out Year for AMBS. We started in January in the .10 to 13 cent range, and we are still hovering at .10 cents now. For the market to give credence to Gerald's future guidance, it really needs to see some increase in shareholder value pretty soon! Maybe the $2.00 pps hope by December was childish gullibility on the parts of some shareholders. But Gerald himself is responsible for building shareholder expectations that our pps would be much higher than .10 cents by Q4 2014 when we're expected to up list.
Let's get the show on the road!!
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼